Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.RSV.preF shedding and safety study
NCT03795441Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad26.RSV.preF in respiratory syncytial virus infection (RSV), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Participants with Presence of Ad26.RSV.preF (shedding) as Assessed by qPCR at Day 183. Started Jan 2019; status: completed.
02
Drugs
Ad26.RSV.preF
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03795441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795441.